SAR302503 + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hematopoietic Neoplasm
Conditions
Hematopoietic Neoplasm
Trial Timeline
Dec 1, 2011 → Jun 1, 2014
NCT ID
NCT01437787About SAR302503 + Placebo
SAR302503 + Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Hematopoietic Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT01437787. Target conditions include Hematopoietic Neoplasm.
What happened to similar drugs?
1 of 2 similar drugs in Hematopoietic Neoplasm were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01437787 | Phase 3 | Completed |
Competing Products
20 competing products in Hematopoietic Neoplasm